Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New supplement aims to rebuild knee cartilage – early trial underway

NCT ID NCT07323745

Disease control Sponsor: Universiti Sains Malaysia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether Mobithron Advance, a daily oral supplement made from undenatured type II collagen, can slow or reverse cartilage loss in people with knee osteoarthritis. Over 12 months, 84 participants will take either the supplement or a placebo. Researchers will use MRI scans to measure cartilage thickness and track pain scores, aiming to see if the drug can modify the disease rather than just ease symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
undenatured type II collagen (UC-II) oral tablets
What this could lead to
If it works, this could point toward a treatment that slows or reverses cartilage loss in knee osteoarthritis, potentially reducing pain and delaying the need for surgery.
What could go wrong
This is a very early (Phase 1) trial with only 84 people, so results may not be conclusive. The supplement may not work better than placebo, and long-term safety is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 84 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males and female patients above 50 years old at the time of recruitment. * OA Diagnosis: Patients with one or both knee osteoarthritis according to clinical and radiological criteria of the American College of Rheumatology (ACR). * OA Grade: Kellgren Lawrence grade 1-3 Exclusion Criteria: * Secondary arthritis (e.g., rheumatoid arthritis, psoriatic arthritis). * History of joint surgery. * Patients who received steroid injection treatment within the last 3 months or hyaluronic acid injection treatment within the last 6 months. * Contraindications to Mobithron Advance (e.g., known allergies, severe liver or kidney disease). * Patients planning for knee surgery within the research period. * Patients on pharmacological treatment for osteoarthritis, other than rescue analgesic agent, e.g: glucosamine, chondroitin, oral steroid

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoarthritis (OA) of the knee are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteoarthritis (OA) of the knee

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Univerisiti Sains Malaysia (HUSM)

    RECRUITING

    Kota Bharu, Kelantan, 16150, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.